While several preclinical studies reported differential drug sensitivities between the glycolytic BCR-DLBCL and the OXPHOS subtypes, these concepts remain in their infancy and much research, both preclinical and clinical, is required [57,58,59,108]. The gene discussed is BCR; the disease is diffuse large B-cell lymphoma.